Immunohistochemistry demonstrated estrogen and progesterone receptor positivity, human epidermal growth factor receptor 2 (HER2) negativity, and a low proliferative index, consistent with a luminal A subtype. Following multidisciplinary tumour board discussion, adjuvant chemotherapy was omitted, considering advanced age and performance status. Here, ERBB2 is linked to neoplasm.